Oxaliplatin is a unique platinum derivative with anti-tumor activity in a number of malignancies, with neurotoxicity being a frequent side effect. Neurotoxicity can manifest in an acute phase and a chronic phase. The acute phase usually presents as dysesthesias of the hands and feet, jaw tightness, and pharyngolaryngo-dysesthesia, triggered and exacerbated by physical contact with cold temperatures. Although various other symptoms have been reported in the literature, little details are available. We report here, in detail, a case of blepharoptosis which appeared after repeated oxaliplatin infusions, and the disappearance of which seemed to be dependent on the infusion rate.
Eloxatin® Package Insert. Bridgewater, NJ: Sanofi-Aventis, U.S. LLC, 2006.
2.
Land SR, Kopec JA, Cecchini RS et al. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. J Clin Oncol2008; 25(16): 2205-11.
3.
Leonard G., Wright M., Quinn M. et al. Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer. BMC Cancer2005; 5: 116.
4.
Cunningham D. , Rao S., Starling N. et al. Randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric (OG) cancer: The REAL 2 trial. J Clin Oncol2006; 24: 18S.
5.
La Verde N., Garassino MC, Spinelli G. et al. Reversible palpebral ptosis following oxaliplatin infusion. Dig Liver Dis2007; 39(11): 1041.
6.
Mariani G., Garrone O., Granetto C., et al. Oxaliplatin induced neuropathy: could gabapentin be the answer?Proc Am Soc Clin Oncol2000: 19: (abstr 2397).
7.
Wilson RH, Lehky T., Thomas RR et al. Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol2002; 20(7): 1767-74.
8.
Wasif Saif M. , Hashmi S.Successful amelioration of oxaliplatin-induced hyperexcitability syndrome with the antiepileptic pregabalin in a patient with pancreatic cancer. Cancer Chemother Pharmacol2008; 61(3): 349-54.
9.
O’Dea D., Handy C., Wexler A. et al. Ocular changes with oxaliplatin. J Clin Oncol Nurs2006 ; 10(2): 227-9.
